// App-Quantinova.ai

4504 : Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).

Researchers

Presenter

  • Toni K. Choueiri

Principal Investigators

  • Sumanta Kumar Pal

  • David F. McDermott

  • David A. Ramies

  • Stephanie Morrissey

  • Yihua Lee

  • Dale Miles

  • Jaymes Holland

  • Janice P. Dutcher

Medical Centers

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute/Brigham and Womens Hospital, Harvard Medical School, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

  • City of Hope, Duarte, CA

  • St. Luke's Roosevelt Hospital, New York, NY

Locations

  • United States

Companies

  • Exelixis, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Renal cell carcinoma

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Cabozantinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved